1. Home
  2. NU vs EW Comparison

NU vs EW Comparison

Compare NU & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Holdings Ltd.

NU

Nu Holdings Ltd.

N/A

Current Price

$12.13

Market Cap

61.8B

Sector

Finance

ML Signal

N/A

Logo Edwards Lifesciences Corporation

EW

Edwards Lifesciences Corporation

N/A

Current Price

$105.39

Market Cap

61.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NU
EW
Founded
2013
1958
Country
Brazil
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.8B
61.6B
IPO Year
2016
1999

Fundamental Metrics

Financial Performance
Metric
NU
EW
Price
$12.13
$105.39
Analyst Decision
Buy
Buy
Analyst Count
23
30
Target Price
$17.81
★ $113.68
AVG Volume (30 Days)
★ 75.2M
4.4M
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.61
Revenue
N/A
★ $6,067,600,000.00
Revenue This Year
$227.31
$12.23
Revenue Next Year
$21.36
$9.84
P/E Ratio
★ $33.29
$65.45
Revenue Growth
N/A
★ 11.55
52 Week Low
$11.20
$74.66
52 Week High
$18.98
$108.00

Technical Indicators

Market Signals
Indicator
NU
EW
Relative Strength Index (RSI) 43.87 71.25
Support Level $11.42 $82.21
Resistance Level $14.60 N/A
Average True Range (ATR) 0.50 3.44
MACD 0.10 0.51
Stochastic Oscillator 49.51 85.90

Price Performance

Historical Comparison
NU
EW

About NU Nu Holdings Ltd.

Nu Holdings Ltd is a Brazilian financial technology firm that offers digital banking services. Its services include Retail credit, SME credit, Payments, Customer assets, Insurance brokerage, E-commerce marketplace, and Mobile virtual network operator. It operates in single operating segment and geographically it operates in Brazil, Mexico, and Other countries with the majority of revenue deriving from Brazil.

About EW Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Share on Social Networks: